$Jumia Technologies (JMIA.US)$
I will temporarily withdraw according to my rule.
It's still difficult~![]()
I will temporarily withdraw according to my rule.
It's still difficult~
Translated
8
$Jumia Technologies (JMIA.US)$ $Jumia Technologies (JMIA.US)$
this is it, isn't it? is it a rebound or a reversal?
I want it to be a cat pretending to be dead, but be careful![]()
I think I want to get out at a good place![]()
It's very helpful!
Thank you very much 😊
this is it, isn't it? is it a rebound or a reversal?
I want it to be a cat pretending to be dead, but be careful
I think I want to get out at a good place
It's very helpful!
Thank you very much 😊
Translated
5
$Serve Robotics (SERV.US)$ I want it to go up a little more even though it's my own fault for re-entering for the second time.
$Serve Robotics (SERV.US)$
$Serve Robotics (SERV.US)$
Translated
2
2
$Jumia Technologies (JMIA.US)$ $Jumia Technologies (JMIA.US)$
I'm back!![]()
After a small loss, I increased my buy position.
Feeling good.![]()
I'm back!
After a small loss, I increased my buy position.
Feeling good.
Translated
4
$NVIDIA (NVDA.US)$
It has boosted my poor investing skills since February.
Full of gratitude for the split.![]()
It has boosted my poor investing skills since February.
Translated
20
$Moderna (MRNA.US)$
Revival!![]()
Moderna's candidate drug selected for FDA Rare Disease Pilot Program
By Colin Keller
Moderna's mRNA-3705 has been selected for a pilot program by the Food and Drug Administration to address a rare genetic disease of the liver pharmaceutical candidate.
Moderna stated on Thursday that mRNA-3705 has been selected by the FDA Center for biological evaluation and research for the development acceleration under the Rare Disease Therapeutics Accelerator program (START Program) as one of the four investigational drugs to artificially promote the development of a treatment for methylmalonic acidemia derived from methylmalonic-CoA mutase.
Revival!
Moderna's candidate drug selected for FDA Rare Disease Pilot Program
By Colin Keller
Moderna's mRNA-3705 has been selected for a pilot program by the Food and Drug Administration to address a rare genetic disease of the liver pharmaceutical candidate.
Moderna stated on Thursday that mRNA-3705 has been selected by the FDA Center for biological evaluation and research for the development acceleration under the Rare Disease Therapeutics Accelerator program (START Program) as one of the four investigational drugs to artificially promote the development of a treatment for methylmalonic acidemia derived from methylmalonic-CoA mutase.
Translated
4
Translated
4
2
Translated
11
2